Shopping Cart
Remove All
Your shopping cart is currently empty
Glecirasib
(Synonyms: KRAS G12C inhibitor 36, JAB-21822, JAB21822, JAB-21000, JAB21000) Copy Product Info
🥰Excellent
Synonyms: KRAS G12C inhibitor 36, JAB-21822, JAB21822, JAB-21000, JAB21000
Catalog No. T78651 Copy Product Info
Purity: 99.7%
🥰Excellent
Glecirasib (JAB-21822) is an orally active KRAS G12C inhibitor that selectively binds to and suppresses the activity of KRAS G12C mutant proteins, thereby inhibiting KRAS G12C-dependent signaling pathways. Glecirasib exhibits high selectivity, potent inhibition, and favorable safety, and is primarily used in studies of non-small cell lung cancer (NSCLC), colorectal cancer (CRC), and pancreatic ductal adenocarcinoma (PDAC).
Cas No. 2657613-87-9
Customer service consultation
| Pack Size | Price | USA Stock | Global Stock | Quantity |
|---|---|---|---|---|
| 1 mg | $113 | - | In Stock | |
| 5 mg | $278 | - | In Stock | |
| 10 mg | Inquiry | - | In Stock | |
| 25 mg | Inquiry | - | In Stock | |
| 50 mg | Inquiry | Inquiry | Inquiry |
For In stock only · Estimated delivery: USA Stock (1-2 days) Global Stock (5-7 days)
Add to Quotation
With extensive experience in compound synthesis, we can provide rapid custom synthesis services for this product according to your research needs.
For research use only—not for human use. No sales to individuals. Use as intended only.
Batch Information
Select Batch
Purity:99.7%
Appearance:Solid
Color:Yellow
Contact us for more batch information
Product Introduction
Bioactivity
Chemical Properties
Storage & Solubility Information
| Description | Glecirasib (JAB-21822) is an orally active KRAS G12C inhibitor that selectively binds to and suppresses the activity of KRAS G12C mutant proteins, thereby inhibiting KRAS G12C-dependent signaling pathways. Glecirasib exhibits high selectivity, potent inhibition, and favorable safety, and is primarily used in studies of non-small cell lung cancer (NSCLC), colorectal cancer (CRC), and pancreatic ductal adenocarcinoma (PDAC). |
| Targets & IC50 | KRas (G12C):1.6 nM |
| In vitro | Methods: KRAS G12C mutant cells were treated with a gradient concentration of Glecirasib and cetuximab in combination for 6 days, followed by cell viability assessment using the CellTiter-Glo assay. Results: A significant synergistic effect was observed in colorectal cancer cells when Glecirasib combined with cetuximab. [1] |
| In vivo | Methods: Glecirasib (10 mg/kg, oral, once a day, 3 weeks) was used to treat NCI-H1373 xenograft mice, and the tumor growth and body weight growth in the mice were observed. Results: Glecirasib inhibited tumor growth in the NCI-H1373 xenograft mouse model and had no significant effect on the body weight of the mice, indicating high safety. [1-3] |
| Synonyms | KRAS G12C inhibitor 36, JAB-21822, JAB21822, JAB-21000, JAB21000 |
| Molecular Weight | 640.03 |
| Formula | C31H26ClF4N7O2 |
| Cas No. | 2657613-87-9 |
| Smiles | N#CC=1C(=O)N(C=2N=C(C(Cl)=CC2C1N3CCN(C(=O)C=C)CC3)C=4C(F)=C(F)C(F)=C(F)C4N)C=5C(=NC=CC5C)C(C)C |
| Storage | Store at low temperature Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
Calculator
In Vivo Formulation Calculator (Clear solution)
Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:
For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, and a total of 10 animals are to be administered, using a formulation of 
10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH2O , the resulting working solution concentration would be 2 mg/mL.Stock Solution Preparation:
Dissolve 2 mg of the compound in 100 μL DMSO to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
Preparation of the In Vivo Formulation:
1) Add 100 μL of the DMSO stock solution to 400 µL PEG300 and mix thoroughly until the solution becomes clear.
2) Add 50 µL Tween 80 and mix well until fully clarified.
3) Add 450 µL Saline,PBS or ddH2O and mix thoroughly until a homogeneous solution is obtained.
This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Preview
Related Tags: Glecirasib chemical structure | Glecirasib in vivo | Glecirasib in vitro | Glecirasib formula | Glecirasib molecular weight
Generate Quote
Catalog No.: Cas No.:
Add
| Size | Quantity | Unit Price | Amount | Operation |
|---|
Generate Quote
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.